InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.93
(
-0.46%
)
Bitcoin
53,849.92
(
-5.51%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 3911

Saturday, 06/23/2007 4:11:27 PM

Saturday, June 23, 2007 4:11:27 PM

Post# of 19309
Largest Biopharmaceutical Classes
(Sales figures are worldwide for 2006.)

01* EPO $11.9B (Aranesp, Epogen, Procrit, NeoRecormon)
02. Cancer mAbs $10.6B (Rituxan, Avastin, Herceptin, Erbitux, etc.)
03. TNF-a $10.3B (Remicade, Enbrel, Humira)
04. Insulin and analogs $10.0B (many products)
05. Recombinant plasma proteins $4.7B (e.g. NovoSeven)
06. Interferon beta $4.4B (Avonex, Rebif, Beteseron)
07. G-CSF $4.4B (Neupogen, Neulasta)
08* hGH $2.5B (many products)
09. Interferon alpha $2.3B (Pegasys, Peg-Intron)
10. Enzyme replacement $1.7B (e.g. Cerezyme)
11. Antiviral mAb $1.1B (Synagis)
12. FSH $1.0B (Gonal-f, Puregon)

Total 2006 sales of these classes: approximately $65B.

*Follow-on biologic has been approved.

Source: http://www.pipelinereview.com/Top_20_Biologics_by_La_Merie.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up